List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 1607 studies with search of: Doxorubicin OR liposomal OR Doxil[TREATMENT] AND HIV [CONDITION]
Hide studies that are not seeking new volunteers.
Hide studies with unknown recruitment status.
  Display Options
Rank Status Study
1 Completed Comparison of Liposomal Doxorubicin Used Alone or in Combination With Bleomycin Plus Vincristine in the Treatment of Kaposi's Sarcoma in Patients With AIDS
Conditions: Sarcoma, Kaposi;   HIV Infections
Interventions: Drug: Doxorubicin hydrochloride (liposomal);   Drug: Filgrastim;   Drug: Bleomycin sulfate;   Drug: Vincristine sulfate
2 Completed Use of Stealth Liposomal Doxorubicin HCl ( DOX-SL ) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma.
Conditions: Sarcoma, Kaposi;   HIV Infections
Intervention: Drug: Doxorubicin hydrochloride (liposomal)
3 Completed Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma
Conditions: Sarcoma, Kaposi;   HIV Infections
Interventions: Drug: Doxorubicin hydrochloride (liposomal);   Drug: Bleomycin sulfate;   Drug: Vincristine sulfate
4 Unknown † A Comparison of DOX-SL Versus Adriamycin Plus Bleomycin Plus Vincristine in the Treatment of Severe AIDS-Related Kaposi's Sarcoma
Conditions: Sarcoma, Kaposi;   HIV Infections
Interventions: Drug: Doxorubicin hydrochloride (liposomal);   Drug: Bleomycin sulfate;   Drug: Vincristine sulfate;   Drug: Doxorubicin hydrochloride
5 Recruiting Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi's Sarcoma
Condition: Sarcoma, Kaposi
Interventions: Drug: Liposomal Doxorubicin;   Drug: Bevacizumab
6 Completed A Study of DOX-SL in the Treatment of AIDS-Related Kaposi's Sarcoma
Conditions: Sarcoma, Kaposi;   HIV Infections
Intervention: Drug: Doxorubicin hydrochloride (liposomal)
7 Recruiting A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer
Conditions: Cancer;   Carcinoma;   Fallopian Tube Cancer;   Gynecological Malignancies;   Metastases;   Oncology;   Ovarian Cancer;   Solid Tumors;   Tumors
Interventions: Drug: A1: AMG 386 10 mg/kg + Liposomal doxorubicin;   Drug: A3: AMG 386 15mg/kg + Liposomal doxorubicin;   Drug: B1: AMG 386 10 mg/kg + Topotecan;   Drug: B3: AMG 386 15mg/kg + Topotecan
8 Terminated MK-4827 in Combination With Pegylated Liposomal Doxorubicin in Participants With Advanced Solid Tumors and Ovarian Cancer (MK-4827-011)
Condition: Ovarian Cancer
Intervention: Drug: MK-4827 + pegylated liposomal doxorubicin
9 Completed Ph 3 Randomized Study of Telcyta® + Liposomal Doxorubicin Vs Liposomal Doxorubicin in Platinum Refractory or Resistant Ovarian Cancer
Condition: Ovarian Neoplasms
Interventions: Drug: TLK286 (Telcyta) HCI for Injection;   Drug: Doxorubicin HCI Liposome Injection
10 Recruiting Study of Pazopanib and Doxil in Patients With Advanced Relapsed Platinum-Sensitive or Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Adenocarcinoma
Conditions: Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Carcinoma
Interventions: Drug: Pazopanib;   Drug: Doxil
11 Active, not recruiting A Study of Liposomal Doxorubicin With or Without IMC-3G3 in Platinum-refractory or Resistant Advanced Ovarian Cancer
Condition: Ovarian Neoplasms
Interventions: Biological: IMC-3G3;   Drug: liposomal doxorubicin
12 Active, not recruiting Phase I Study of DOXIL and Temsirolimus in Resistant Solid Malignancies
Condition: Resistant Solid Malignancies
Intervention: Drug: temsirolimus & pegylated liposomal doxorubicin
13 Completed Efficacy and Safety Study of M200(Volociximab in Combination With Liposomal Doxorubicin)
Conditions: Ovarian Cancer;   Primary Peritoneal Cancer
Intervention: Drug: M200 (Volociximab), Doxorubicin
14 Unknown † Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural Mesothelioma
Condition: Malignant Pleural Mesothelioma
Interventions: Drug: Liposomal doxorubicin;   Drug: Cisplatin
15 Not yet recruiting Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC)
Condition: Breast Cancer
Interventions: Drug: Liposomal Doxorubicin;   Drug: Seliciclib
16 Recruiting Carfilzomib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: carfilzomib and pegylated liposomal doxorubicin;   Drug: carfilzomib and pegylated liposomal doxorubicin hydrochloride;   Drug: Carfilzomib and PLD Efficacy
17 Completed Cisplatin HAI Study in Patients With Advanced Cancer and Dominant Liver Involvement
Condition: Advanced Cancer
Interventions: Drug: Cisplatin;   Drug: Liposomal Doxorubicin
18 Recruiting Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma
Condition: Sarcoma
Intervention: Drug: temsirolimus (Torisel) plus liposomal doxorubicin (Doxil)
19 Withdrawn A Phase I/II Study of Liposomal Doxorubicin (Doxil)/Melphalan/Bortezomib (Velcade) in Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Liposomal Doxorubicin/Melphalan/Bortezomib
20 Completed Combination Study Of SB-485232 (Interleukin 18) And Doxil For Advanced Stage Epithelial Ovarian Cancer
Conditions: Primary Peritoneal Carcinoma;   Epithelial Ovarian Carcinoma;   Neoplasms, Ovarian;   Fallopian Tube Cancer
Intervention: Drug: SB-485232 (interleukin 18), pegylated liposomal doxorubicin

Previous Page Studies Shown (1-20) Next Page (21-40)
† Indicates status has not been verified in more than two years
Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
RSS Feeds for studies found by your search that were:
  First received in the last 14 days,  
  Last updated (includes received) in the last 30 days
  Download Options




Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services